Founded in Europe with over 40 years of experience, NUVISAN is a fully integrated contract research and development, and manufacturing organisation (CRO/CDMO) that offers unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain. On April 1, 2024, the global leader in testing, ALS Limited, acquired NUVISAN, integrating advanced drug discovery, preclinical and clinical development capabilities into its growing portfolio. NUVISAN serves clients in early and clinical development, supporting pharmaceutical and biotech companies, academic institutes, and other CROs.

Services include:
- Contract Development and Manufacturing (CDMO)
- Preclinical and Clinical Development
- Drug Discovery Services
- Active Pharmaceutical Ingredients (API) Production
- Regulatory Affairs Consulting
- Analytical Services
- Quality Control and Assurance
- Project Management

In conclusion, NUVISAN stands as a comprehensive partner for the pharmaceutical industry, providing an extensive range of services to enhance drug development processes. For more information, please visit nuvisan.com.